A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)

IF 12.9 1区医学 Q1 HEMATOLOGY

Blood Cancer Journal Pub Date : 2025-06-17 DOI:10.1038/s41408-025-01296-8

Chandramouli Nagarajan, Wei-Ying Jen, Melissa Ooi, Sanjay De Mel, Cinnie Soekojo, Sung Soo Yoon, Melinda Tan, Yunxin Chen, Xinhua Li, Yogesh Pokharkar, Shi Ning Tham, Nur Shahidah Binte Hashim, Neha Awasthi, Sarah M. Burkill, Brian Durie, Wee Joo Chng

引用次数: 0

Abstract

Trial Registration: NCT03153036

Abstract Image

查看原文本刊更多论文

Daratumumab联合沙利度胺和地塞米松治疗复发和/或难治性骨髓瘤（RRMM）的2期研究

试验注册：NCT03153036

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Cancer Journal ONCOLOGY-

CiteScore

16.70

自引率

2.30%

发文量

153

审稿时长

>12 weeks

期刊介绍： Blood Cancer Journal is dedicated to publishing high-quality articles related to hematologic malignancies and related disorders. The journal welcomes submissions of original research, reviews, guidelines, and letters that are deemed to have a significant impact in the field. While the journal covers a wide range of topics, it particularly focuses on areas such as: Preclinical studies of new compounds, especially those that provide mechanistic insights Clinical trials and observations Reviews related to new drugs and current management of hematologic malignancies Novel observations related to new mutations, molecular pathways, and tumor genomics Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways.